Shanghai Henlius Biotech (FRA:2E8) Payments of Debt: €-456.6 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2E8 Shanghai Henlius Biotech Inc FRA:2E8
50 GF Score
Price €7.30
GF Value €3.38
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Henlius Biotech Payments of Debt?

Shanghai Henlius Biotech FRA:2E8 -2.67% 50 Payments of Debt is €-456.6 Mil as of Dec. 2025. GuruFocus rates FRA:2E8 with a GF Score™ of 50/100 and a GF Value™ of €3.38 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Shanghai Henlius Biotech's Payments of Debt for the six months ended in Dec. 2025 was €-285.9 Mil.

Shanghai Henlius Biotech's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was €-456.6 Mil.

Shanghai Henlius Biotech Payments of Debt Related Terms

Shanghai Henlius Biotech Payments of Debt Historical Data

* Premium members only.

The historical data trend for Shanghai Henlius Biotech's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Henlius Biotech Payments of Debt Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only -180.03 -241.76 -275.75 -404.22 -457.32

Shanghai Henlius Biotech Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -146.79 -210.44 -188.66 -170.75 -285.85
FRA:2E8
50GF Score
Shanghai Henlius Biotech Inc FRA:2E8
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Henlius Biotech Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-456.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-456.6 Mil mean?
Shanghai Henlius Biotech (FRA:2E8) has a Payments of Debt of €-456.6 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Shanghai Henlius Biotech and its competitors.
Is Shanghai Henlius Biotech's Payments of Debt too high?
Shanghai Henlius Biotech's current Payments of Debt is €-456.6 Mil. Overall, Shanghai Henlius Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's Payments of Debt compare to VRTX and REGN?
Shanghai Henlius Biotech's Payments of Debt of €-456.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Shanghai Henlius Biotech and its competitors. Shanghai Henlius Biotech's current Payments of Debt is €-456.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (FRA:2E8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.38, compared to a current price of €7.30 — trading 116% above its estimated fair value. The current Payments of Debt is €-456.6 Mil. Shanghai Henlius Biotech's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Shanghai Henlius Biotech (FRA:2E8), the current Payments of Debt is €-456.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Henlius Biotech (FRA:2E8) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued. The current stock price of €7.30 is trading 116% above its estimated GF Value™ of €3.38. GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.

Key valuation signals for FRA:2E8:

  • Payments of Debt: €-456.6 Mil
  • GF Value™: €3.38 vs. price of €7.30 (116% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the FRA:2E8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Henlius Biotech Business Description

Other Exchanges 02696:Hong Kong
Address B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
50GF Score

Get the complete analysis for FRA:2E8

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.30
Price
€3.38
GF Value